Objective: To systemically assess the efficacy and safety of Tongxinluo capsule combined with clopidogrel in treatment of angina pectoris. Method: Such databases as CBM

CNKI and Wanfang data were electronically searched to collect relevant randomized controlled trials (RCTs). According to the inclusion and exclusion criteria

two reviewers independently screened literature

extracted data

and assessed the methodological quality of included studies. Then

Meta-analysis was conducted using RevMan 5.2.6 software. Result: The 10 RCTs with 867 patients were included. Tongxinluo capsule combined with clopidogrel had a better efficacy on angina pectoris than clopidogrel alone [OR=4.01

95%CI (2.68

5.99)]

with statistically significant difference between the two groups (P<0.000 01). There was no statistically significant difference in electrocardiography (ECG) efficacy between Tongxinluo capsule combined with clopidogrel and clopidogrel alone [OR=1.67

95%CI (0.94

2.98)

P=0.08]. The subgroup analyses based on regimen in the control group showed that

compared with clopidogrel alone group

the Tongxinluo capsule combined with clopidogrel group had a higher efficacy on angina pectoris

with statistically significant difference between the two groups [OR=6.95

95%CI (3.87

12.69)

P<0.000 01]. Compared with clopidogrel combined with inosine group

the Tongxinluo capsule combined with clopidogrel group had a higher efficacy on angina pectoris

with statistically significant difference between the two groups [OR=2.61

95%CI (1.06

6.40)

P<0.05]. Indirect treatment comparison showed that there was no significant difference in efficacy on angina pectoris between clopidogrel alone group and Tongxinluo capsule alone group [OR=1.19

95%CI (0.42

3.39)

P>0.05]. Conclusion: Existing evidences suggest that Tongxinluo capsule combined with clopidogrel is effective and safe in improving angina pectoris. However

the quality of RCTs is not high

so more randomized double-blind clinical trials with high quality are still needed for further verification.